Ginkgo Bioworks (DNA) said Tuesday it is partnering with Deep Origin on a 4.5-year project funded by advanced Research Projects Agency for Health, or ARPA-H, to develop a computational platform for predicting drug safety.

Under the collaboration, Ginkgo Bioworks said it will use its Datapoints platform to produce high-throughput data sets for training AI models, including small-molecule and genetic perturbation data across multiple cell and tissue types.

Readouts will include cell type-specific toxicity endpoints, transcriptomics and cell-painting, the company said.

Price: 9.52, Change: +0.12, Percent Change: +1.22